When the Board Needs to Replace the CEO Mid-Trial
There is no governance decision more consequential — or more feared — than the board-initiated replacement of a CEO while a clinical trial is in progress. It combines the difficulty of any CEO transition with a set of constraints that make the difficulty significantly worse: a scientific program that cannot be paused, a team whose confidence in leadership directly affects execution quality, investors whose appetite for governance disruption is limited, and regulatory counterparties who are watching the company's institutional stability with careful attention.
Most boards that face this situation are not prepared for it. They have not discussed the conditions that would require it, have not established the governance process for executing it, and have not thought through the specific risks that a mid-trial leadership transition creates. When the moment arrives — and it arrives for a meaningful proportion of clinical-stage companies — the board is forced to make one of its most important decisions in conditions of maximum stress and minimum preparation.
This article does not make the argument that replacing a CEO mid-trial is always wrong or always avoidable. Sometimes it is necessary — and delaying a necessary leadership change because the timing is inconvenient is itself a governance failure with real consequences. What it does argue is that the decision requires a governance process that is more rigorous, more deliberate, and more carefully managed than boards typically apply to it.
Why Boards Defer — and What That Deferral Costs
The instinct to defer a CEO replacement decision when a clinical trial is underway is understandable. The board is looking at a running experiment whose outcome the company is depending on, a team that is executing under pressure, and a set of external relationships — with investigators, with CROs, with regulators — that are built partly on confidence in the current leadership. Introducing a leadership change into that environment feels like adding risk to an already risk-laden situation.
But deferral has its own costs, and they are frequently underestimated.
A CEO who has lost the board's confidence does not suddenly perform better because a trial is running. The behaviors or decisions that created the loss of confidence continue to accumulate costs — in team morale, in strategic clarity, in investor relations, in the quality of the board's own engagement with the company. A board that has privately concluded that the CEO needs to be replaced but has deferred acting on that conclusion is not protecting the trial. It is allowing a known problem to run unchecked while hoping the trial concludes before the cost becomes visible.
There is also a specific risk that is rarely named: the CEO who senses the board's diminished confidence — as most perceptive leaders will — is operating in a destabilized state. Their decision-making quality in that state is typically worse than their baseline. The deferral intended to protect the trial may be actively undermining the judgment of the person running it.
The Conditions That Justify Acting Mid-Trial
Not every CEO performance concern justifies a mid-trial transition. The governance question is whether the cost of acting now is lower than the cost of deferring — a calculation that requires honest assessment of both sides.
The conditions that most clearly justify acting despite the timing are those where the CEO's continued presence creates a risk that is more severe than the disruption of transition.
Integrity violations are the clearest case. A CEO who has misrepresented data to the board, to regulators, or to investors cannot be managed through the end of a trial. The regulatory and legal exposure of allowing them to continue — and to continue signing off on regulatory correspondence, investor communications, and data representations — is a risk the board cannot accept regardless of where the trial is in its timeline. Acting immediately, with documented process, is the only defensible governance response.
Material operational failures that are traceable to leadership and that are actively harming trial execution represent a second category. If the CEO's management of the CRO relationship, the clinical operations team, or the regulatory function is creating problems that are degrading the quality or the timeline of the trial, the board's instinct to protect the trial by avoiding disruption may be exactly backward. The disruption of replacing the CEO may be less damaging than the ongoing cost of the operational failure.
Loss of investor confidence that threatens the financing runway is a third category. A clinical trial that cannot be completed because the company runs out of capital is a worse outcome than a mid-trial leadership transition. If the CEO has become an obstacle to the financing the company needs to complete its program, the board may face a situation where acting on the leadership question is a precondition for solving the capital question.
Voluntary departure — which is not strictly a board-initiated replacement but often involves the same governance challenges — can occur at any point regardless of trial timing. A CEO who receives and accepts an attractive external opportunity, or who decides for personal reasons that they can no longer continue, creates the same operational challenge regardless of whether the board would have made a different choice. The governance framework for managing it is substantially the same.
The Process: Deliberation Before Decision
If the board has concluded that the CEO needs to be replaced and that the timing, however difficult, cannot be deferred, the governance process for executing the decision matters as much as the decision itself.
Convene independently. The board's deliberation about a CEO replacement should happen in executive session, without the CEO present, and the record of that deliberation should be carefully managed. The board needs to reach a clear and documented consensus — not a plurality with reservations — before any action is taken. A board that is divided going into a CEO transition, or that has individual members who are uncertain about the decision, will find those divisions amplified in the aftermath. The time to resolve internal disagreement is before the transition begins.
Identify the interim leader before the conversation with the CEO. The single most destabilizing gap in a CEO transition is the period between the departure decision and the identification of operational leadership. In a clinical-stage company with an active trial, even a brief period of genuine leadership vacuum creates risks — to team morale, to ongoing decisions about trial management, to external relationships that require an authoritative point of contact. The board should identify, and if possible confirm, who will serve as interim CEO before the departure conversation with the current CEO takes place. This may be a board member, a senior internal executive, or an identified external executive who can step in on short notice. The specifics matter less than the fact that the succession is ready.
Manage the clinical operations dimension explicitly. Before acting, the board should understand — in some detail — which aspects of the trial's ongoing management are most dependent on the CEO's direct involvement and what the plan is for continuity in each of those areas. The chief medical officer, clinical operations lead, and regulatory affairs lead should each be spoken with, confidentially, before the transition occurs — not about the pending decision, but about their own roles, their confidence in the program, and what they would need from leadership to continue executing effectively. This assessment serves two purposes: it informs the board's view of the transition risk, and it positions the board to provide tailored support to the people who will carry the program through the transition.
Prepare the investor communication with the same rigor as the decision itself. Investors in a clinical-stage company learn about a CEO transition with heightened alertness. They will ask what it means for the trial, whether it signals data concerns they have not been told about, and whether the board has a credible plan for what comes next. The communication should be proactive rather than reactive, should be specific about what the interim and search process looks like, and should address the trial explicitly — not by offering false reassurance, but by giving investors a clear account of what continuity measures are in place and who is accountable for what.
The Departure Conversation
The conversation in which the board communicates the decision to the CEO is one of the most consequential moments in the governance process. How it is conducted affects not only the CEO's response but the narrative that travels through the company and the industry in the days that follow.
The conversation should be conducted by the board chair, or by the lead independent director if the chair has a prior relationship that complicates their role. It should be direct and unambiguous — the decision has been made, it is not a negotiation. It should be respectful of the CEO as a person, regardless of the circumstances that led to the decision. And it should address, concretely, the terms of the transition: the announcement timing, the departure package, the extent and duration of any ongoing engagement the board is requesting to support continuity, and the agreed narrative.
The agreed narrative is important and often neglected. A CEO who feels blindsided or treated poorly will not stay within the agreed narrative, and a messy public version of the departure damages the company's credibility with the investors, partners, and employees who are watching. Spending time in the departure conversation on the narrative — even when the circumstances are adverse — is governance work with direct operational value.
In situations involving integrity violations, the departure conversation is necessarily more constrained. Legal counsel should be involved in structuring both the conversation and the documentation, and the agreed narrative may be more limited than in a performance-based departure. The board's obligation to the company's legal and regulatory position takes precedence over the normal courtesies of the departure process, while still treating the individual with basic dignity.
What Comes After: Stabilizing the Organization
The period immediately following a CEO departure is the most organizationally vulnerable point of the transition. The board's attention is often absorbed by the search process, but the most important governance work in this period is stabilization — ensuring that the company can continue to execute while the search proceeds.
The interim leader needs explicit authority. They should be introduced to the organization, to investors, and to external partners as the person in charge — not as a caretaker maintaining the status quo until the real decision is made. Interim leaders who are not given genuine authority cannot make the decisions the organization needs, and organizations that sense their interim leader lacks real authority enter a period of informal holding patterns that is damaging to execution.
Key team members need direct engagement from the board. The departure of a CEO creates a period of uncertainty that prompts the company's most valuable people to evaluate their own situations. The board members who have relationships with the clinical, scientific, and regulatory leads should make direct contact — not to provide information about the search, but to express the board's commitment to the program, to acknowledge that the transition is disruptive, and to ask what those individuals need to continue functioning effectively. This is not management — it is governance. And in a mid-trial transition, it is governance that has direct effects on scientific outcomes.
The Search: Speed and Quality in Tension
The CEO search following a mid-trial transition is constrained in ways that most searches are not. The company cannot wait twelve to eighteen months for the ideal candidate. It needs a credible permanent leader quickly enough that the interim period does not become its own source of organizational drift.
This tension between speed and quality is real, and boards that deny it tend to resolve it in one of two ways: they move too fast and hire someone who looks adequate under time pressure but proves inadequate when the trial concludes and a different set of leadership demands emerges, or they move too slowly and allow the interim period to extend until it becomes a source of instability in its own right.
The most effective resolution is a search that is ruthlessly focused on the specific profile the company needs for the next stage — defined, as discussed in earlier work on succession planning, before the search begins rather than during it — and that is willing to make a clear offer to the best available candidate for that profile rather than waiting for a candidate who satisfies every criterion.
Perfect is rarely available. What is always available is a clear-eyed assessment of the most important capabilities the company needs, and a search process focused tightly on finding someone who credibly possesses them.
The Governance Lesson
The hardest version of the mid-trial CEO replacement is the one that was not prepared for — where the board had no succession infrastructure, no clarity about what the next leader needed to look like, and no prior conversation about the conditions that would require action. These situations are managed through improvisation, and the improvisation usually shows.
The governance lesson is not subtle: the work that makes a mid-trial CEO transition survivable is done long before the transition becomes necessary. Boards that have built succession infrastructure, that have had explicit conversations about the conditions requiring CEO replacement, and that have maintained relationships of trust and direct communication with the clinical and scientific leadership of the company are positioned to navigate even this hardest transition with their programs intact.
The ones that have not done that work discover its value at exactly the moment they can no longer acquire it.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on governance structure and leadership transitions across clinical-stage life sciences companies.